Clinical Trial Update: A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of ABI-6250 in healthy participants for hepatitis D is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D
• Hepatitis Delta Virus

Drugs mentioned

• ABI-6250

Snippet

Sponsor: Assembly Biosciences | Conditions: Hepatitis Delta Virus, Hepatitis D | Phase 1 | Status: COMPLETED